A clinical stage company focused on developing novel radiotherapeutics for the treatment of cancer. Fusion is a spin-out from the Centre for Probe Development and Commercialization (CPDC) at McMaster University, Hamilton.
Novel bio-therapeutics for the treatment of cancer: Turnstone Biologics extends the boundaries of the emerging field of cancer immunotherapy. Turnstone’s Maraba virus technology is a first-in-class tumour targeted oncolytic vaccine. Building on the recent clinical validation of OVs, the Maraba virus technology combines potent tumour killing effects with the benefits of a cancer vaccine, increasing anti-tumour immunity.
A novel platform technology that simultaneously detects solid tumours using MRI and sensitizes cancer cells for maximized radiation therapy performance
Nanology Labs has developed a low toxicity MRI contrast agent which circumvents limitations of other agents currently available. The agent, Manganescan™, uses nanoparticles containing manganese to illuminate early stage tumors, including those in the brain.
The development and commercialization of novel cancer therapies targeting the WDR5 protein, essential for assembly of methyltransferase complexes and proper histone modification. The overexpression of WDR5 and resulting deregulation of epigenetic mechanisms are implicated in various cancers and correlated with poor patient survival.
A biotherapeutics company focused on developing and commercializing therapies that improve patient outcomes in difficult-to-treat cancers. Their current focus is on the development of promising small molecule drug candidates for haematological cancers.
This novel, best-in-class orally bioavailable proteosome inhibitor is being developed for the treatment of multiple myeloma and other cancers.
This software platform, called Privacy Analytics Risk Assessment Tool (PARAT), unlocks the vast potential of data on diseases and patient care without compromising individual privacy.
An Accelerator enterprise formed to expedite proof-of-concept (PoC) and development of pre-IND cancer therapies, advancing in-licensed, clinically enabled oncology assets with high-value potential in a shared risk model for the purpose of out-licensing or selling the technology to create value. Triphase has formed a strategic partnership with Celgene Corporation to enable the rapid development of PoC in important new cancer therapies of mutual interest.
A unique analytical instrument for high throughput and highly multiplexed analyses of biomarkers for research, clinical trials and personalized medicine.
ReFilx™ is a novel polymeric soft tissue filler that provides breast cancer patients with a cosmetically superior, minimally-invasive and cost-effective solution for the permanent restoration of breast defects following lumpectomy.
PITCH PRESENTER: Soror Sharifpoor, Polumiros Inc.
2017: Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer
The novel platform delivers sustained and amplified viral-mediated cell killing specific to pancreatic cancer (PCa) via the production of PCa cell-targeted amiR-containing exosomes.
PITCH PRESENTER: Brian Keller, Carolina Ilkow, The Ottawa Hospital Research Institute
Further development of promising potent compounds in triple-negative breast cancer models.
Development of a universally compatible (allogeneic) source for the next generation of CAR-T therapies based on hematopoietic stem cells harvested from healthy donors.
Further development of novel cyclic and heterocyclic hydrazone-based linkers for antibody-drug-conjugates (ADC). These compounds allow “tuning” of the drug-release properties of the ADC to optimize various properties, such as plasma stability and lysosome drug release, according to the desired application(s).
Further validation of novel diagnostic gene test to predict which patients benefit from anthracycline chemotherapy.
Clinical validation of a novel breast cancer screening algorithm that can identify select screening mammograms as ‘benign and requiring no further review’, thereby reducing the need for a radiologist consult.
Development of DT-1 class of small molecules which possess selective cancer cell-killing activity and reduced toxicity due to a unique “cloaking” mechanism.
The platform intends to make it easier for stakeholders to form public and private data sharing networks, and systematize genotype-phenotype associations, patient matching, and recruitment through deterministic search and machine learning algorithms.
Development of multi-spectral X-ray imagers that improve the quality and accuracy of chest X-rays, while helping to reduce the demand for CT cancer diagnostics.
Innovative solid-state PEM system that produces a higher resolution of the breast, while reducing radiotracer dose, compared to competitive PEM system.
A bioinformatics software platform that enables informed and actionable clinical decision by facilitating the interpretation and translation of tumor genomic sequencing data using comprehensive databases.
An economical port, bag and belt system for urostomy patients that aims to reduce their rate of complications, facilitate application, and reduce social stigma; overall helping improve the quality of life of bladder cancer patients.
PITCH PRESENTER: Dr. Nicholas Power, London Health Sciences Centre
Evaluation of novel potassium channel antagonists, initially developed for neurodegenerative disorders, as cancer therapeutics.
Evaluation of survival benefit and preclinical proof of concept of a novel ganglioside-based cancer vaccine.
Development of novel CYP26 inhibitors for the treatment of leukemia and myeloma with potential greater specificity and less toxicity than current inhibitors.
A mobile health application that seeks to merge tracking of patients’ side effects and situations related to cancer treatments with patient-provider communication.
PITCH PRESENTER: Danielle Paes, FocusONCare
A new manufacturing process that creates microbubbles that are only responsive to the ultrasound frequency used in cancer treatment, enabling significantly lower volumes and costs while potentially improving safety.
PITCH PRESENTER: Dr. Naomi Matsuura, Sunnybrook Research Institute
Evaluation of a Nanostring gene expression assay across three centres for its analytical reproducibility and accuracy in potentially guiding the selection of patient-specific therapies for early breast cancers.
Use of clinical low frequency ultrasound for monitoring tumour response in women receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Evaluation of immune responses engendered in CEA transgenic mice by a vaccine formulation composed of a recombinant CEA N domain antigen and advanced adjuvant.
Support for the use of Cell-Mate Technology in a clinical trial for the Genome Canada project entitled "Early detection of patients at high risk of esophageal adenocarcinoma".
CellaxTM is a drug-polymer conjugate nanoparticle that when injected, selectively accumulates in tumours resulting in increased therapeutic benefits and reduced side effects.
A system using ultrasound to both detect and treat tumours in bone and liver for the relief of pain without surgery and without expensive imaging equipment.